Cargando…
Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876828/ https://www.ncbi.nlm.nih.gov/pubmed/24455206 http://dx.doi.org/10.1155/2013/379252 |
_version_ | 1782297548963184640 |
---|---|
author | Fraeman, Kathy H. Nordstrom, Beth L. Luo, Weixiu Landis, Sarah H. Shantakumar, Sumitra |
author_facet | Fraeman, Kathy H. Nordstrom, Beth L. Luo, Weixiu Landis, Sarah H. Shantakumar, Sumitra |
author_sort | Fraeman, Kathy H. |
collection | PubMed |
description | This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemotherapy exposure and nonexposure. Cox models sought predictors of new-onset hypertension severity among baseline and chemotherapy exposure variables. New-onset hypertension was observed in about one-third of 25,090 patients with various cancer types. The incidence rates (IR) of severe and crisis-level hypertension, respectively, were the highest in patients with gastric (18.5 cases per 100 person-years (PY), 5.6 per 100 PY) and ovarian cancer (20.2 per 100 PY, 4.8 per 100 PY). The highest IR of moderate hypertension was observed in patients with renal cancer (46.7 per 100 PY). Across all cancers, chemotherapy exposure was associated with a 2–3.5-fold increase in risk of any degree of hypertension compared to periods of no chemotherapy; higher hypertension levels showed greater variability in relative risks by type and line of therapy but indicated an overall increase associated with chemotherapy exposure. These results help to elucidate the factors influencing HTN among cancer patients and the incidence of HTN relative to chemotherapy exposure. |
format | Online Article Text |
id | pubmed-3876828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38768282014-01-16 Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study Fraeman, Kathy H. Nordstrom, Beth L. Luo, Weixiu Landis, Sarah H. Shantakumar, Sumitra Int J Hypertens Research Article This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemotherapy exposure and nonexposure. Cox models sought predictors of new-onset hypertension severity among baseline and chemotherapy exposure variables. New-onset hypertension was observed in about one-third of 25,090 patients with various cancer types. The incidence rates (IR) of severe and crisis-level hypertension, respectively, were the highest in patients with gastric (18.5 cases per 100 person-years (PY), 5.6 per 100 PY) and ovarian cancer (20.2 per 100 PY, 4.8 per 100 PY). The highest IR of moderate hypertension was observed in patients with renal cancer (46.7 per 100 PY). Across all cancers, chemotherapy exposure was associated with a 2–3.5-fold increase in risk of any degree of hypertension compared to periods of no chemotherapy; higher hypertension levels showed greater variability in relative risks by type and line of therapy but indicated an overall increase associated with chemotherapy exposure. These results help to elucidate the factors influencing HTN among cancer patients and the incidence of HTN relative to chemotherapy exposure. Hindawi Publishing Corporation 2013 2013-12-16 /pmc/articles/PMC3876828/ /pubmed/24455206 http://dx.doi.org/10.1155/2013/379252 Text en Copyright © 2013 Kathy H. Fraeman et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Fraeman, Kathy H. Nordstrom, Beth L. Luo, Weixiu Landis, Sarah H. Shantakumar, Sumitra Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title | Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title_full | Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title_fullStr | Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title_full_unstemmed | Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title_short | Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study |
title_sort | incidence of new-onset hypertension in cancer patients: a retrospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876828/ https://www.ncbi.nlm.nih.gov/pubmed/24455206 http://dx.doi.org/10.1155/2013/379252 |
work_keys_str_mv | AT fraemankathyh incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy AT nordstrombethl incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy AT luoweixiu incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy AT landissarahh incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy AT shantakumarsumitra incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy |